• Korean Journal of Veterinary Research
• /
• v.52 no.3
• /
• pp.209-211
• /
• 2012

A 5-year-old castrated male Shih-tzu dog and a 9-year-old intact female Schnauzer dog were presented with anorexia and depression. These 2 dogs were diagnosed based on which criteria as primary immune-mediated hemolytic anemia (IMHA). Blood examination showed anemia, spherocytosis, auto-agglutination and total bilirubinemia in 2 cases. These dogs were recovered by treatment of mycophenolate mofetil and prednisolone, and showed good prognosis until now. Mycophenolate mofetil is recommended as initial treatment in canine IMHA.

• Journal of Veterinary Clinics
• /
• v.40 no.4
• /
• pp.276-282
• /
• 2023

Immune-mediated polyarthritis (IMPA) is an inflammatory, noninfectious disease that affects two or more joints in dogs. Immunosuppressive doses of prednisolone are considered the initial treatment choice for dogs with IMPA. However, few reports have described the combination of mycophenolate mofetil and prednisolone for treating dogs with IMPA. In this report, we described the cases of three dogs treated with a combination of mycophenolate mofetil and prednisolone. The clinical signs were alleviated in all cases, and C-reactive protein levels were reduced after treatment. Our results show that combination therapy of mycophenolate mofetil and prednisolone is effective in managing IMPA. However, careful monitoring of the potential adverse effects, including sporadic infections and metabolic diseases, is necessary. In addition, screening tests and appropriate treatments are necessary for proteinuria, a common complication in dogs with IMPA.

• Annals of Clinical Neurophysiology
• /
• v.9 no.2
• /
• pp.105-107
• /
• 2007

• Korean Journal of Veterinary Research
• /
• v.63 no.2
• /
• pp.8.1-8.3
• /
• 2023

A 13-year-old neutered male Maltese dog presented to our hospital with lethargy and anorexia. Laboratory abnormalities included severe non-regenerative anemia (hematocrit, 12.9%; reticulocyte count 12.8 K/µL). The cytology of bone marrow revealed erythroid hypercellularity with mild myelofibrosis. Therefore, late-stage precursor-targeted immune-mediated anemia (PIMA) was diagnosed. Multimodal treatment including 2 immunosuppressant drugs (prednisolone and mycophenolate mofetil), antithrombic drug (clopidogrel), and blood transfusion was performed. The dog showed complete remission from PIMA, and the total duration of follow-up was 622 days. This is the first case report of canine PIMA managed successfully with prednisolone and mycophenolate mofetil in Korea.

• Korean Journal of Clinical Pharmacy
• /
• v.20 no.2
• /
• pp.151-158
• /
• 2010

Therapeutic drug monitoring of Mycophenolate mofetil(MMF) has been suggested in some clinical trials, but has not been widely adopted in Korea. The purpose of this study was to analyze the withdrawal rates of MMF and determine the characteristics of the patients who experienced adverse reactions with MMF therapy and to suggest the criteria for selecting patients who need monitoring of MMF levels. We retrospectively collected data of patients who started MMF between July 2007 and June 2008. A total of 154 adult patients were included in our study. Among them, ninety seven patients discontinued MMF with 59 cases being due to adverse drug reactions. Thirty one patients required dosage reduction of MMF with twenty three cases being due to adverse reactions. Twenty six patients continued the MMF without or with mild adverse reactions. Of the 82 adverse reaction cases, hematologic adverse reactions accounted for 38 cases (46%) and gastrointestinal (GI) adverse reactions accounted for 28 cases (34%). Older age and lower serum albumin levels were significantly different characteristics between the patients who withdraw MMF due to hematological adverse reactions and those who were able to continue therapy. The group who experienced GI adverse reactions had higher MMF dosages based on body weight and lower serum albumin levels. In conclusion, the factors affecting the adverse reactions of MMF were age, serum albumin level and higher dosage, therefore therapeutic drug monitoring of MMF should be considered in these patients.

• Journal of the korean veterinary medical association
• /
• v.48 no.10
• /
• pp.627-630
• /
• 2012

• Journal of Veterinary Clinics
• /
• v.23 no.3
• /
• pp.344-348
• /
• 2006

A 5-year-old, male Yorkshire terrier dog was presented with progressive seizure and anorexia. Definitive diagnosis of necrotizing meningoencephalitis(NME) was made based on characteristic clinical features, brain lesion with MRI, and histopathologic examination. The dog was treated with prednisolone for 20 days, firstly. Prednisolone and mycophenolate mofetil(MMF) were then administered for 40 days following the initial therapy. However, the clinical signs were not improved and seizure frequency was increased. This patient survived around 2 months after diagnosis. This case report described the clinical findings, imaging characteristics and pathologic features of NME in a Yorkshire terrier with trial treatment using MMF.

• Journal of Microbiology and Biotechnology
• /
• v.34 no.2
• /
• pp.249-261
• /
• 2024

New anti-lung cancer therapies are urgently required to improve clinical outcomes. Since ganodermanontriol (GDNT) has been identified as a potential antineoplastic agent, its role in lung adenocarcinoma (LUAD) is investigated in this study. Concretely, lung cancer cells were treated with GDNT and/or mycophenolate mofetil (MMF), after which MTT assay, flow cytometry and Western blot were conducted. Following bioinformatics analysis, carboxylesterase 2 (CES2) was knocked down and rescue assays were carried out in vitro. Xenograft experiment was performed on mice, followed by drug administration, measurement of tumor growth and determination of CES2, IMPDH1 and IMPDH2 expressions. As a result, the viability of lung cancer cells was reduced by GDNT or MMF. GDNT enhanced the effects of MMF on suppressing viability, promoting apoptosis and inducing cell cycle arrest in lung cancer cells. GDNT up-regulated CES2 level, and strengthened the effects of MMF on down-regulating IMPDH1 and IMPDH2 levels in the cells. IMPDH1 and IMPDH2 were highly expressed in LUAD samples. CES2 was a potential target for GDNT. CES2 knockdown reversed the synergistic effect of GDNT and MMF against lung cancer in vitro. GDNT potentiated the role of MMF in inhibiting tumor growth and expressions of CES2 and IMPDH1/2 in lung cancer in vivo. Collectively, GDNT suppresses the progression of LUAD by activating CES2 to enhance the metabolism of MMF.

• Journal of Veterinary Clinics
• /
• v.32 no.4
• /
• pp.366-369
• /
• 2015

A 12-year-old, castrated male, mixed-breed dog was referred to us with a history of depression, lameness, neck and multiple joints pain. Clinical signs had been deteriorating from rear limbs lameness leading to pain on all four limbs lameness for 7 days. Mild leukocytosis and increased C-reactive protein concentration were revealed in blood work. On radiography, degenerative change of humerus and cervical intervertebral space narrowing were found. The results of synovial fluid analysis revealed severe neutrophilic pleocytosis, decreased viscosity, increased turbidity and bacterial culture was negative. The antinuclear antibody test was negative and MRI results revealed mild cervical intervertebral disk disease (IVDD). Based on all tests, we diagnosed this case as idiopathic immune-mediated polyarthritis (IMPA). Prednisolone and mycophenolate mofetil were administered and clinical signs were resolved after 7 days. This case report demonstrated that clinical, diagnostic imaging and synovial fluid analysis findings and successful treatment result with prednisolone and mycophenolate mofetil in canine idiopathic IMPA.

• Journal of Veterinary Clinics
• /
• v.33 no.5
• /
• pp.290-294
• /
• 2016

A 13-month-old intact female poodle dog presented with an acute history of circling and seizure episodes. On the basis of the results of neurologic examination combined with magnetic resonance imaging and cerebrospinal fluid analysis (CSF), meningoencephalitis of unknown etiology (MUE) was suspected. Therapy with mycophenolate mofetil plus prednisolone was initiated, following which the clinical signs showed improvement for only one month before gradually worsening again. Acute progression of the clinical disease was observed, and the patient was euthanized 91 days after initial presentation. This case was definitively diagnosed as necrotizing meningoencephalitis (NME) according to the results of post-mortem histopathological examination. This report describes the clinical findings, serial magnetic resonance imaging (MRI) characteristics, and histopathological changes in a case of acute NME.